Peptidyl-Prolyl Isomerase 1 Regulates Ca(2+) Handling by Modulating Sarco(endo)plasmic Reticulum Calcium ATPase and Na(2+)/Ca(2+) Exchanger 1 Protein Levels and Function

V Sacchi
B Wang
D Kubli
A Martinez
J Jin

See next page for additional authors

Follow this and additional works at: https://touroscholar.touro.edu/nymc_fac_pubs
Part of the Enzymes and Coenzymes Commons, and the Medical Physiology Commons

Recommended Citation

This Article is brought to you for free and open access by the Faculty at Touro Scholar. It has been accepted for inclusion in NYMC Faculty Publications by an authorized administrator of Touro Scholar. For more information, please contact jogrady@nymc.edu.
Peptidyl-Prolyl Isomerase 1 Regulates Ca\(^{2+}\) Handling by Modulating Sarco(Endo)Plasmic Reticulum Calcium ATPase and Na\(^{2+}/Ca\(^{2+}\) Exchanger 1 Protein Levels and Function

Veronica Sacchi, PhD; Bingyan J. Wang, MS; Dieter Kubli, PhD; Alexander S. Martinez, BS; Jung-Kang Jin, PhD; Roberto Alvarez, Jr, BS; Nirmala Hariharan, PhD; Christopher Glombotski, PhD; Takafumi Uchida, PhD; James S. Malter, MD; Yijun Yang, PhD; Polina Gross, PhD; Chen Zhang, MD; Steven Houser, PhD; Marcello Rota, PhD; Mark A. Sussman, PhD

Background—Aberrant Ca\(^{2+}\) handling is a prominent feature of heart failure. Elucidation of the molecular mechanisms responsible for aberrant Ca\(^{2+}\) handling is essential for the development of strategies to blunt pathological changes in calcium dynamics. The peptidyl-prolyl cis-trans isomerase peptidyl-prolyl isomerase 1 (Pin1) is a critical mediator of myocardial hypertrophy development and cardiac progenitor cell cycle. However, the influence of Pin1 on calcium cycling regulation has not been explored. On the basis of these findings, the aim of this study is to define Pin1 as a novel modulator of Ca\(^{2+}\) handling, with implications for improving myocardial contractility and potential for ameliorating development of heart failure.

Methods and Results—Pin1 gene deletion or pharmacological inhibition delays cytosolic Ca\(^{2+}\) decay in isolated cardiomyocytes. Paradoxically, reduced Pin1 activity correlates with increased sarco(endo)plasmic reticulum calcium ATPase (SERCA2a) and Na\(^{2+}/Ca\(^{2+}\) exchanger 1 protein levels. However, SERCA2a ATPase activity and calcium reuptake were reduced in sarcoplasmic reticulum membranes isolated from Pin1-deficient hearts, suggesting that Pin1 influences SERCA2a function. SERCA2a and Na\(^{2+}/Ca\(^{2+}\) exchanger 1 associated with Pin1, as revealed by proximity ligation assay in myocardial tissue sections, indicating that regulation of Ca\(^{2+}\) handling within cardiomyocytes is likely influenced through Pin1 interaction with SERCA2a and Na\(^{2+}/Ca\(^{2+}\) exchanger 1 proteins.

Conclusions—Pin1 serves as a modulator of SERCA2a and Na\(^{2+}/Ca\(^{2+}\) exchanger 1 Ca\(^{2+}\) handling proteins, with loss of function resulting in impaired cardiomyocyte relaxation, setting the stage for subsequent investigations to assess Pin1 dysregulation and modulation in the progression of heart failure. (J Am Heart Assoc. 2017;6:e006837. DOI: 10.1161/JAHA.117.006837.)

Key Words: cardiomyocyte • Na\(^{+}/Ca\(^{2+}\) exchange • peptidyl-prolyl isomerase 1 • sarcoplasmic reticulum Ca\(^{2+}\)-ATPase

Ca\(^{2+}\) is a ubiquitous intracellular second messenger exerting several fundamental roles in the myocardium, including control of cardiomyocyte mechanical behavior and programmed cell death, as well as regulation of pathological hypertrophic remodeling through Ca\(^{2+}\)/calmodulin-dependent kinase II (CaMKII) signaling.\(^1,2\) Ca\(^{2+}\)-dependent signaling is highly regulated in cardiomyocytes and determines force of cardiac muscle contraction. Ca\(^{2+}\) uptake and release is profoundly altered in failing hearts, resulting in impaired contractility and fatal cardiac arrhythmias.\(^3,4\) Considering the
Clinical Perspective

What Is New?

- This study reveals a novel role for peptidyl-prolyl isomerase 1 in modulating the expression and function of Ca\(^{2+}\)-handling proteins sarco(endo)plasmic reticulum calcium ATPase and Na\(^{+}/Ca\(^{2+}\)) exchanger 1, with peptidyl-prolyl isomerase 1 loss of function resulting in impaired cardiomyocyte relaxation.

What Are the Clinical Implications?

- Decreased peptidyl-prolyl isomerase 1 activity could contribute to impairment of Ca\(^{2+}\) cycling in the heart, resulting in diminished contractile function under stress and loss of inotropic responsiveness in the failing heart. Cardiac-specific peptidyl-prolyl isomerase 1 overexpression could serve as a molecular interventional strategy to normalize Ca\(^{2+}\) handling within cardiomyocytes laboring under pathological stress.

Crucial role of Ca\(^{2+}\) in regulating cardiac muscle contraction, much attention has been paid to understanding the role of defects in Ca\(^{2+}\) regulation in heart failure (HF). Impaired sarcoplasmic reticulum (SR) Ca\(^{2+}\) uptake causes deterioration to both systolic and diastolic heart function. Ca\(^{2+}\) removal from the cytosol occurs by both sarco(endo)plasmic reticulum calcium ATPase (SERCA2a)–mediated uptake and sarcolemmal extrusion, mainly via Na\(^{+}/Ca\(^{2+}\)) exchanger 1 (NCX-1). During homeostasis, the amount of Ca\(^{2+}\) recycled by the SR in the relaxation phase equals the amount released, and influx of Ca\(^{2+}\) equals the amount extruded. In HF, SERCA2a function is decreased and NCX-1 activity is enhanced, causing impaired relaxation, which leads to reductions of SR Ca\(^{2+}\) load and cardiomyocyte contractility. Cardiac contractility was improved in preclinical and clinical trials by viral overexpression of SERCA2a; it can be exploited as a target in the failing heart. This study highlights a novel function of Pin1 in the heart as a regulator of Ca\(^{2+}\) handling by controlling Ca\(^{2+}\) recycling through modulation of SERCA2a and NCX-1 protein levels and function. Inclusion of Pin1 as a novel regulator of cardiomyocyte calcium dynamics opens up novel potential avenues for molecular interventional approaches to normalize calcium homeostasis in the pathological myocardium.

Methods

Mice

Pin1\(^{+/−}\) and Pin1\(^{−/−}\) mice were obtained from Dr Takafumi Uchida (Tohoku University, Miyagi, Japan) and from Dr James Malter (University of Texas Southwestern, Dallas, TX). Nontransgenic (wild-type [WT]) C57/B6 mice were used as controls. Mice enrolled in the study were aged 6–7 months of age, and no differences in the baseline global phenotype were observed in nontransgenic and transgenic mice. An n=5 animals/group was used for the experiment described in Figure 1, whereas an n=3 animals/group was used for all other experiments. All animal protocols and studies were approved by the institutional review board of the Animal Care and Use Committee at San Diego State University (San Diego, CA).

Ca\(^{2+}\) Cycling and Contractility Assessment

Left ventricular cardiomyocytes, isolated as previously described, were placed in a heated bath at 31°C on the stage of inverted microscopes for contractility and Ca\(^{2+}\) transients. Cells were bathed continuously with Tyrode solution containing 1 mmol/L CaCl\(_2\), and the myocyte field was stimulated at 1 Hz. Sarcomere shortening was measured with an IonOptix system, whereas intracellular Ca\(^{2+}\) handling was assessed in cells loaded with 0.57 μmol/L Fluo-4 AM.
with an epifluorescence system. Setups were coupled with Digidata or DI-155 interface and pClamp or WinDaq software. Data were analyzed with pClamp or LabChart software. Fluo-4 signals were expressed as normalized fluorescence (\(F/F_0\)), where \(F_0\) is the diastolic fluorescent level subtracted by the background signal measured in the region adjacent to the cell, as described.\(^{16,17}\) To assess Ca\(^{2+}\) cycling in response to short-term Pin1 inhibition, isolated cardiomyocytes were pretreated for 2 hours with either Pin1 inhibitor (1 \(\mu\)mol/L juglone) or water as vehicle control before intracellular Ca\(^{2+}\) handling measurement at room temperature.

**Immunoblot Analysis**

Whole heart lysates were prepared by homogenizing tissues in lysis buffer containing 1 mol/L Tris-HCl (pH 7.4), 5 mol/L NaCl, 100 mmol/L EDTA, and 100 mmol/L EGTA, supplemented with protease and phosphatase inhibitor cocktails.
using a Next Advance bullet blender at 4°C. Tissue homogenates were transferred to clean tubes, Triton X-100 was added at 1% final concentration, and lysates were incubated on ice for 60 minutes. Homogenates were centrifuged at 16,100g, and supernatants were collected for further experiments. Adult cardiomyocytes were isolated, as previously described.18 Cardiomyocytes were treated with either Pin1 inhibitor (10 nmol/L; or 1 µmol/L juglone) or water as vehicle control for 2 hours. Afterwards, medium was removed and isolation buffer containing 1 mol/L Tris-HCl (pH 7.4), 5 mol/L NaCl, 100 mmol/L EDTA, 100 mmol/L EGTA, and 1% Triton X-100, supplemented with protease and phosphatase inhibitor cocktails, was added to the cells for isolating proteins by cell scraping. Tissue and cell lysates were stored at −80°C until further use. Protein concentration was determined by Bradford assay using BSA standards and normalized to the samples having the lowest protein concentration. Proteins lysates were prepared by adding LDS Sample Buffer with 50 mmol/L dithiothreitol. Samples were boiled for 5 minutes at 70°C to denature proteins. Proteins were separated by SDS-PAGE (15–20% g in each gel lane) and 1% Triton X-100, supplemented with protease and phosphatase inhibitor cocktails, was added to the cells for isolating proteins by cell scraping. Tissue and cell lysates were stored at −80°C until further use. Protein concentration was determined by Bradford assay using BSA standards and normalized to the samples having the lowest protein concentration. Proteins lysates were prepared by adding LDS Sample Buffer with 50 mmol/L dithiothreitol. Samples were boiled for 5 minutes at 70°C to denature proteins. Proteins were separated by SDS-PAGE (15–20 µg in each gel lane) and transferred to Immobilon-FL polyvinylidene difluoride membranes. Primary antibodies were incubated overnight in TBS Blocking Buffer at 4°C, and secondary antibodies were incubated for 90 minutes at room temperature in blocking buffer. Fluorescent signals were detected using a Scanning Odyssey CLX and quantified using software. Antibodies and dilutions are listed in Table S1.

In Silico Analysis of SERCA2a and NCX-1 Proteins to Identify Putative Pin1 Binding Sites

SERCA2a and NCX-1 murine protein sequences were selected from the Protein National Center for Biotechnology Information Database. The accession number for SERCA2a was NP_033852.1, and for NCX-1, NP_035536.2. The presence of serine next to a proline is highlighted by a black square, whereas the presence of a threonine next to a proline is highlighted by a red square.

Proximity Ligation Assay

Proximity ligation assay was performed as previously described.12,19–22 Briefly, hearts fixed in 10% formalin were embedded in paraffin, sectioned at a thickness of 4 µm, and stained for Pin1 and Serca2a/Ncx-1 primary antibodies. Isolated cardiomyocytes, as described in Immunoblot analysis section, were fixed in 4% paraformaldehyde and permeabilized with 0.3% Triton X-100 before proceeding with primary antibody staining. Signal was detected using Duolink In Situ Detection Reagent and Probes. Myosin light chain 2 was used to visualize myocardium. Antibody manufacturers and dilutions are listed in Table S1. Duolink In Situ Mounting Medium with 4’,6-diamidino-2-phenylindole was used to counterstain nuclei and coverslip. Scans consisted of Z-stack random regions for each heart analyzed using an SP8 Confocal Microscope using 40× objective. The number of events was quantified using the ImageJ particles counting tool in each field.

Glutathione S-Transferase and Glutathione S-Transferase–Pin1 Recombinant Protein Production

Recombinant glutathione S-transferase (GST) protein was purchased. The expression plasmid for GST-Pin1 was also purchased. GST-Pin1 protein was produced with minor adaptation. One Shot Top10 Escherichia coli cells were transformed and amplified in Luria-Bertani (LB) medium containing ampicillin at 100 µg/mL overnight at 37°C, 67 g overnight. The optical density at 600 optical density was measured by a biophotometer and adjusted with fresh LB medium between 0.4 and 0.6 optical density because less growth or overgrowth will affect future GST-Pin1 protein expression. LB (400 mL) and 1 mol/L isopropyl β-D-thiogalactopyranoside (400 µL) were added to the culture and incubated for another 5 hours at 37°C, 67 g. The bacteria pellets were thereafter obtained by centrifugation at 0°C, 1015 g for 25 minutes. Bacteria pellets were diluted 1:1 in lysis buffer containing 50 mmol/L Tris-HCl (pH 7.5), 100 mmol/L NaCl, and 5 mmol/L dithiothreitol, supplemented with protease and phosphatase inhibitor cocktails. They were lysed by sonication using 10 short pulses (5–10 seconds), followed by 30-second pauses to reestablish a low temperature. Cell debris was removed by centrifugation at 0°C, 4872 g for 25 minutes. GST-Pin1 protein was purified from crude lysates using the Pierce GST Spin Purification Kit, according to the manufacturer’s instructions. Protein expression was confirmed by immunoblot for GST, as described in the Immunoblot Analysis subsection of the Methods section.

Pull-Down Assay

Pull-down assay using GST-Pin1 was performed with minor adaptation. Briefly, cardiomyocytes were isolated from WT mice and incubated in 1 mL of lysis buffer containing 50 mmol/L HEPES (pH 7.4), 150 mmol/L NaCl, 10% glycerol, 1% Triton X-100, 1.5 mmol/L MgCl2, 1 mmol/L EGTA, 100 mmol/L NaF, 1 mmol/L Na3VO4, and 1 mmol/L dithiothreitol, supplemented with protease and phosphatase inhibitor cocktails for 30 minutes at 4°C on a rotator. Cell lysates were centrifuged at 16,100g for 20 minutes at 4°C to pellet cell debris, and 200 µL of supernatant was transferred to a clean 1.5-mL tube for each assay. GST or GST-Pin1 fusion protein at 2 µmol/L was added to supernatant, and samples were rotated...
at 4°C for 1 hour. GST beads (20 μL) were added to the samples and rotated at 4°C for 1 hour. GST beads were pelleted by centrifugation at 9300g and washed 3 times with 1 mL of lysis buffer. Afterwards, lysis buffer was removed and beads were resuspended in 20 μL of LDS Sample Buffer with 50 mmol/L dithiothreitol. Samples were boiled for 5 minutes at 70°C to denature proteins, GST beads were pelleted by centrifugation at 9300g, and supernatant was applied to the SDS-PAGE gel. Immunoblot was performed, as described above, using primary antibody dilutions listed in Table S1.

**SR-Membrane Enrichment**

SR-enriched fractions were isolated from WT, Pin1+/−, and Pin1−/− hearts, as previously described, with minor adaptations. Briefly, myocardium was homogenized in buffer containing the following: 5 mmol/L HEPES, 250 mmol/L sucrose, 0.2% sodium azide, and a cocktail of phosphatase and protease inhibitors. The homogenate was centrifuged at 5500 rpm for 1 hour. GST beads were pelleted by centrifugation at 4°C for 1 hour. GST beads were resuspended in 20 μL of LDS Sample Buffer with 50 mmol/L dithiothreitol. Samples were boiled for 5 minutes at 70°C to denature proteins, GST beads were pelleted by centrifugation at 9300g, and supernatant was applied to the SDS-PAGE gel. Immunoblot was performed, as described above, using primary antibody dilutions listed in Table S1.

**SERCA2a ATPase Activity**

SERCA2a Ca²⁺-dependent ATPase activity was measured on 10 μg/mL of SR preparations using the High Throughput Colorimetric ATPase assay kit, according to manufacturer’s instructions. This was done in the presence of 2 μmol/L of the calcium ionophore A23187 and of an escalating concentration of free Ca²⁺ (0–0.5–1–2.5–5–8–10 μmol/L). Reactions were incubated for 30 minutes at room temperature. SERCA-independent Ca²⁺-ATPase activity was measured in the presence of 100 nmol/L of thapsigargin and subtracted from total SR-ATPase activity to calculate specific SERCA2a-ATPase hydrolysis activity. The activity of SERCA2a was calculated as hydrolyzed ATP levels (μmol/L) normalized with protein content (mg) and reaction time (minutes) from 3 independent experiments.

**SR Uptake and Release**

Oxalate-supported Ca²⁺-uptake rates were measured using the Ca²⁺ fluorescent dye indo-1, according to published methods, with minor adaptation for use on a plate reader (SPECTRAmax Plus). Immediately before collection of emission spectra, 25 μg of isolated SR membranes was added to each well. Baseline reads were collected until fluorescence was not stable; then, CaCl₂ was added to each well to produce a consistent starting of [Ca²⁺]₀ of 3.5 μmol/L. Shortly after the attainment of a constant [Ca²⁺]₀, 5 mmol/L ATP was added to each well to initiate Ca²⁺ uptake. Maximum and minimum Ca²⁺-dependent fluorescence was determined after the Ca²⁺ uptake reaction by additions of 250 μmol/L of the Ca²⁺ chelator EGTA and 1 mmol/L of the CaCl₂. 4-Chloro-m-cresol (20 mmol/L) was added to the assay mixture to chemically stimulate Ca²⁺ release in vitro.

**Statistical Analysis**

Data in Figure 1 were represented as median and interquartile ranges; in Figures 2 through 5, as mean±SEM; and in Figure 6, as median and interquartile ranges. Statistical analysis was performed using the unpaired Student t test or 1-way ANOVA, with a Dunnett post-hoc test to compare each group with a control group using GraphPad Prism version 5.0. When normality or equal variance was not met, nonparametric analysis was performed using a Mann-Whitney rank sum test. P<0.05 was considered statistically significant.

**Results**

**Ca²⁺ Transient Decay Is Delayed in Pin1−/− Cardiomyocytes**

Cardiomyocytes from WT and Pin1−/− mice were isolated to assess the consequences of systemic loss of Pin1 on cardiomyocyte Ca²⁺ cycling and contractile function. Representative superimposed traces of Ca²⁺ transients and sarcomere shortening show Pin1−/− cardiomyocytes possess delayed Ca²⁺ transient decay and slightly longer time to peak compared with WT cardiomyocytes (Figure 1A and 1B). Quantification of Ca²⁺ transient decay (Figure 1E), time-to-peak shortening (Figure 1G), and relaxation (Figure 1H) confirmed a significant delay in Pin1−/− cardiomyocytes compared with WT. Amplitude of Ca²⁺ transient (Figure 1C), TTP Ca²⁺-Transient (Figure 1D), and contractility (Figure 1F) remain unchanged in Pin1−/− cardiomyocytes compared with WT. Collectively, these data indicate loss of Pin1 impairs cardiomyocyte Ca²⁺ cycling, which may play a critical role in supporting systemic hemodynamic demand in vivo.

**SERCA2a and NCX-1 Protein Levels Are Elevated in Pin1-Deficient Hearts**

Ca²⁺ influx and efflux from cardiomyocyte SR and cytosol are tightly regulated by expression of several proteins and their
Phosphorylation status. Because Pin1 influences protein expression levels and phosphorylation, the impact of decreased Pin1 expression on SERCA2a, NCX-1, CaMKII, phosphorylamban, L-type Ca²⁺ channel, and ryanodine receptor 2 protein expression and phosphorylation was assessed using whole heart lysates harvested from WT, Pin1+/−/C0 and Pin1−/−/C0 mice. Pin1+/−/C0 mice express 50% of Pin1 protein compared with WT, and have been included in this study to investigate

Figure 2. Sarco(endo)plasmic reticulum calcium ATPase (SERCA2a) and Na⁺/Ca²⁺ exchanger 1 (NCX-1) protein levels are elevated in peptidyl-prolyl isomerase 1 (Pin1)–deficient hearts. Immunoblot showing SERCA2a (A) and NCX-1 (B) levels significantly increased in Pin1+/− and Pin1−/− hearts compared with wild type (WT). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a loading control. Quantification of protein expression below each representative blot shown as n-fold expression/WT. N=3. Data presented as mean±SEM. *P<0.05, †P<0.01 vs WT (1-way ANOVA, followed by Dunnett post-hoc analysis).

Figure 3. Cardiac sarcoplasmic reticulum (SR) Ca²⁺-ATPase activity and uptake are impaired in peptidyl-prolyl isomerase 1 (Pin1)–deficient hearts. A, Reduced Ca²⁺-dependent ATPase activity by purified Pin1+/− and Pin1−/− cardiac SR membranes determined on the basis of release of inorganic phosphate. Specificity of SR Ca²⁺-ATPase activity assessed in the presence of 100 nmol/L of thapsigargin. B and C, SR Ca²⁺ uptake (B) reduced in Pin1+/− and Pin1−/− isolated SR membranes, whereas SR release (C) was not influenced by Pin1 loss, as measured using the Ca²⁺ fluorescent dye Indo-1. A through C, N=3±SEM. *P<0.05, †P<0.01 vs Pin1+/−; ‡P<0.05, §P<0.01 wild type (WT) vs Pin1+/− (1-way ANOVA, with Dunnett post-hoc test; A). *P<0.05 WT vs Pin1+/−, †P<0.05 WT vs Pin1−/− (1-way ANOVA, followed by Dunnett post-hoc test; B and C).
phenotypic consequences of partial Pin1 deletion on calcium handling. SERCA2a protein level was increased ∼1.5-fold in Pin1+/− and 1.8-fold in Pin1−/− hearts compared with WT (Figure 2A). NCX-1 protein level was elevated 1.6- and 1.7-fold in Pin1+/− and Pin1−/−, respectively, compared with WT (Figure 2B). In comparison, expression and phosphorylation of CaMKII, L-type Ca2+ channels, phospholamban (both pSer16 and pThr17), and ryanodine receptor 2 (both pSer2808 and pSer2814) were unaltered by Pin1 loss (Figure S1A through S1D). These results indicate Pin1 influences SERCA2a and NCX-1 protein levels as a potential explanation to account for delayed Ca2+ transient decay resolution in isolated cardiomyocytes (Figure 1).

Cardiac SERCA2a Function Is Impaired in Pin1-Deficient Hearts

Increased SERCA2a protein level correlates with enhanced Ca2+ uptake, resulting in faster Ca2+ transient decay and relaxation.4 Paradoxically, loss of Pin1 leads to slowing of Ca2+ transient decay (Figure 1) together with elevated SERCA2a protein level (Figure 2). To resolve these superficially discrepant observations, SERCA2a ATPase activity and Ca2+ uptake and release from SR membrane–enriched preparations were measured. Stimulation of Ca2+-dependent SERCA2a ATPase activity was assessed on the basis of release of inorganic phosphate. SERCA2a-independent ATPase activity was evaluated in the presence of SERCA2a inhibitor (thapsigargin) and subtracted from total SERCA2a ATPase activity to calculate specific activity. SERCA2a ATPase activity in Pin1+/− and Pin1−/− is reduced compared with WT when [Ca2+]i is in the range of 5 to 10 μmol/L (Figure 3A). At a 5 μmol/L Ca2+ concentration, SERCA2a activity was 31.7±3.9% for WT samples compared with 23.57±1.08% for Pin1+/− or 23.33±0.21% for Pin1−/− (P<0.05). At an 8 μmol/L Ca2+ concentration, SERCA2a activity was 51.88±3.83% for WT compared with 30.35±0.19% for Pin1+/− or 31.42±1.25% for Pin1−/− (P<0.05). At a 10 μmol/L Ca2+ concentration,
Figure 5. Sarco(endo)plasmic reticulum calcium ATPase (SERCA2a) and Na⁺/Ca²⁺ exchanger 1 (NCX-1) interaction with peptidyl-prolyl isomerase 1 (Pin1) is disrupted by Pin1 inhibition. A and B, SERCA2a (A) and NCX-1 (B) interaction with Pin1 determined by proximity ligation assay on isolated wild-type (WT) cardiomyocytes treated with either Pin1 inhibitor juglone or vehicle control for 2 hours. N=3. C and D, SERCA2a and NCX-1 protein expression dose dependently accumulates in cardiomyocytes treated with juglone for 2 hours compared with cardiomyocytes in culture medium (CM). DAPI indicates 4',6-diamidino-2-phenylindole; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; and MYL2, myosin light chain 2. *P<0.01 vs WT, †P<0.001 vs WT.
SERCA2a activity was 77.29±1.41% for WT compared with 45.14±2.61% for Pin1+/− or 41.67±1.45% for Pin1+/−/− (P<0.01). By fluorimetric assay, the SR membrane Ca2+ uptake rate was reduced ≈25% in Pin1+/− and Pin1+/−/− compared with WT (Figure 3B). Rate of Ca2+ uptake was 83.22±5.3 nmol/L per mg SR membrane/min in WT, but decreased to 62.36±4.22 nmol/L per mg SR membrane/min in Pin1+/− or 66.10±3.717 nmol/L per mg SR membrane/min in Pin1+/−/− (P<0.05; Figure 3B). SR uptake was comparably inhibited by thapsigargin in all WT, Pin1+/−, and Pin1+/−/− samples, confirming reduction in SR Ca2+ uptake in Pin1+/− and Pin1+/−/− membranes with diminished SERCA2a function. In comparison, SR-mediated Ca2+ release was not affected by Pin1 reduction (Figure 3C). Overall, these results indicate SERCA2a ATPase activity and calcium reuptake are reduced by loss of Pin1.

SERCA2a and NCX-1 Interact With Pin1 in Vivo

Pin1 selectively recognizes phosphorylated serine or threonine immediately adjacent to a proline.9−11 Five putative consensus motifs for Pin1 binding were identified on the SERCA2a sequence (Figure S2A). SERCA2a includes Ser661-Pro662, located in the cytoplasmic domain; and 4 Thr-Pro dipeptides (3 at 247/8, 499/500, and 537/8, located in cytoplasmic domains, and 1 at 959/60, located in a luminal domain). One putative consensus motif for Pin1 binding instead is present in NCX-1 at Ser223-Pro224 (Figure S2B), which is located in the extracellular domain. Thus, interaction of Pin1 with Ca2+ cycling proteins SERCA2a and NCX-1 protein was evaluated by proximity ligation assay in paraffin tissue sections from WT hearts (Figure 4A and 4B). Proximity between Pin1 and SERCA2a primary antibodies was detected as ≈4700 distinct interactions compared with ≈10 events detected in control sections stained with only 1 antibody (P<0.001; Figure 4A). Furthermore, Pin1 and NCX-1 interaction events occurred in ≈2700 instances compared with only 18 events in single antibody controls (P<0.001; Figure 4B). Pin1+/−/− hearts used as a negative control also exhibited a similarly low number of events as single antibody negative control. These findings demonstrate cellular in situ molecular interaction between Pin1 and calcium regulatory proteins SERCA2a and NCX-1.

Furthering the hypothesis that Pin1 activity influences SERCA2a and NCX-1 protein expression, isolated
Cardiomyocytes were pretreated for 2 hours with juglone, a highly selective cell-permeable, irreversible inhibitor of PPlases or water as vehicle control. SERCA2a or NCX-1 interaction with Pin1 is disrupted by juglone (Figure 5A and 5B, respectively). Moreover, SERCA2a and NCX-1 protein levels were dose-dependently increased by Pin1 inhibition (Figure 5C and 5D). In fact, treatment with only 10 nmol/L juglone elevated SERCA2a levels by 1.8-fold \( (P < 0.05; \) Figure 5C) and NCX-1 levels by 1.5-fold \( (P < 0.001; \) Figure 5D) compared with vehicle-treated controls. Treatment with a higher juglone concentration of 1 \( \mu \)mol/L juglone elevated SERCA2a levels by 2.5-fold \( (P < 0.001; \) Figure 5C) and NCX-1 levels by 1.9-fold \( (P < 0.001; \) Figure 5D) compared with vehicle-treated controls. SERCA2a and NCX-1 interaction was confirmed by pull-down assay (Figure S3). GST- and GST-Pin1–specific protein expression was confirmed by immunoblot against GST proteins (Figure S3A). Immunoblot for SERCA2a and NCX-1 confirmed specific interaction with Pin1, as for other known targets (Figure S3B). Therefore, Pin1 protein interaction and/or activity influences SERCA2a and NCX-1 protein expression, with loss of Pin1 activity elevating SERCA2a and NCX-1 protein levels.

Cytosolic \( Ca^{2+} \) Removal Is Delayed by Pin1 Inhibition

Delayed \( Ca^{2+} \) decay correlates with impaired cardiomyocyte relaxation, leading to reduced contractility.\(^2,4\) Interaction between SERCA2a or NCX-1 and Pin1 to control cardiomyocyte \( Ca^{2+} \) cycling was assessed by observing \( Ca^{2+} \) transients after Pin1 inhibition by juglone. Representative superimposed traces of \( Ca^{2+} \) transients collected from isolated cardiomyocytes treated for 2h with Juglone or water as vehicle control are shown in Figure 6A. Juglone pretreatment of cardiomyocytes for 2 hours prompted significant delay in \( Ca^{2+} \) transient decay (Figure 6D), whereas \( Ca^{2+} \)-transient amplitude (Figure 6B) and time-to-peak \( Ca^{2+} \) transient (Figure 6C) remained unchanged. These results support the regulatory role of Pin1 in controlling cardiomyocyte \( Ca^{2+} \) cycling through modulation of SERCA2a activity and/or expression.

Discussion

\( Ca^{2+} \) signals regulate cardiomyocyte contraction and multiple critical cellular processes, including gene regulation, proliferation, enlargement, and death.\(^2,4,27\) The exact basis for how a single ion precisely controls such diverse cellular processes remains intriguing.\(^27\) However, there is consensus that the magnitude and temporal signature of \( Ca^{2+} \) signal, as well as the cellular localization of these signals, are critical for proper cardiomyocyte function.\(^27\) Pin1 exhibits the unique property of acting as a rheostat in the molecular signaling network to regulate intensity and duration of signals.\(^7,8\) Findings in this study define a novel role of Pin1 as a fine-tuning mechanism for regulation of \( Ca^{2+} \) dynamics through SERCA2a and NCX-1 proteins.

Decreased \( Ca^{2+} \) reuptake in cardiomyocytes causes impaired myocardial relaxation and slows filling of the ventricle, leading to HF with preserved ejection fraction.\(^4,27\) Results in this study showed that loss of Pin1 activity, by either genetic deletion (Figure 1) or pharmacological inhibition (Figure 6), slows cytosolic \( Ca^{2+} \) clearance in isolated cardiomyocytes. Reduced SERCA2a activity is also a characteristic of HF.\(^4\) SR membranes isolated from Pin1-deficient hearts showed significantly reduced SERCA2a \( Ca^{2+}\)-ATPase activity and uptake (Figure 3). Control of SERCA2a function by Pin1 explains delayed \( Ca^{2+} \) clearance on Pin1 deletion or pharmacological inhibition, substantiating a potential role for Pin1 in contributing to dysregulation of \( Ca^{2+} \) homeostasis associated with HF. Our findings agree with prior studies reporting the pan PPlase inhibitor juglone inhibits SERCA2a \( Ca^{2+}\)-ATPase activity in isolated SR membranes.\(^28\) Decreased Pin1 activity concomitant to acute or chronic stress, where faster \( Ca^{2+} \) cycling is required to sustain increased contractile function, could impair cardiac output and contribute to progression of HF because of loss of inotropic responsiveness. SR ATPase activity and SR \( Ca^{2+} \) uptake were similarly impaired in membranes isolated from Pin1\(^{-/-}\) and Pin1\(^{-/-}\), indicating that loss of \( \approx 50\% \) Pin protein level is sufficient to impair cardiac SERCA2a function. Results herein reveal another facet of the Pin1 signaling in myocardial biological features associated with regulation of \( Ca^{2+} \) handling within cardiomyocytes. PPlase family members other than Pin1, including cyclophylin D and FK-506–binding proteins, regulate \( Ca^{2+} \) handling.\(^14\) Our findings expand known regulatory roles for the PPlase family by incorporating the parvulin family member Pin1 in regulation of \( Ca^{2+} \) handling within myocardium via influences on SERCA2a and NCX-1.

This study reveals 2 novel targets regulating \( Ca^{2+} \) homeostasis in the myocardium influenced by Pin1: SERCA2a and NCX-1 (Figures 4, 5, and S3). Pin1 has been associated with calcium-dependent signaling through interaction with the \( Ca^{2+} \) regulator protein CaMKII in brain tissue, but whether CaMKII function was affected by Pin1 binding remains unresolved.\(^29\) Our hypothesis is that Pin1 binding to SERCA2a and NCX-1 simultaneously influences both protein function and expression through simultaneous modification of conformation and protein turnover, respectively. Indeed, Pin1 might promote stabilization in the active conformation of SERCA2a and NCX-1 proteins, as for other targets, like \( \beta \)-catenin, nuclear factor \( \kappa B \), and p53.\(^9\) In this scenario, Pin1 inhibition would impair SERCA2a and NCX-1 function, which is partially compensated by increased protein production within cardiomyocytes.
Furthermore, Pin1 might also be important for SERCA2a and NCX-1 protein turnover by decreasing stabilization, similar to Pin1-mediated action on CF-2, c-Myc, and cyclin E. Consequently, loss of Pin1 might slow SERCA2a and NCX-1 degradation, resulting in accumulation of protein. The combined impact of SERCA2a- and NCX-1-impaired function, coupled with protein accumulation resulting from diminished Pin1, is consistent with our findings, as summarized in Figure 7. In this model, Pin1 genetic deletion/inhibition reduces overall SERCA2a and NCX-1 protein functional activity, which is only partially compensated by protein accumulation attributable to impaired SERCA2a and NCX-1 degradation. Future studies will investigate molecular mechanisms altering SERCA2a and NCX-1 function on Pin1 loss. SERCA2a was phosphorylated by mass spectrometry in the heart tissue at Ser38 and Ser661. Few studies have shown that SERCA2a can be phosphorylated by CaMKII on Ser38, enhancing enzyme activity. However, later studies using a polyclonal antibody specific for the phosphorylated Ser38 epitope on the SERCA2a Ca2+ ATPase failed to detect the phosphorylated form in both isolated cardiomyocytes and purified SR vesicles. This suggested that Ser38 phosphorylation on SERCA2a is not a significant regulatory feature of SERCA2a activity. No studies have investigated potential consequences of phosphorylation on Ser661 of SERCA2a. NCX-1 was found, by mass spectrometry in the heart tissue, phosphorylated on Ser389. However, no studies have addressed the potential functional consequences of NCX-1 phosphorylation on these specific sites. Protein kinase C phosphorylates NCX-1 in vivo, increasing exchange activity, but the precise phosphorylation site has not been identified. Previous studies have identified phosphorylation on SERCA2a and NCX-1 sites that are not in the putative consensus motifs for Pin1 binding. However, the tryptic digestion performed

Figure 7. The impact of diminished peptidyl-prolyl isomerase 1 (Pin1) activity on cardiomyocyte Ca2+ handling. A, Pin1 binding to sarcoplasmic reticulum calcium ATPase (SERCA2a) and Na+/Ca2+ exchanger 1 (NCX-1) promotes stabilization of active conformation for SERCA2a and NCX-1 proteins as well as protein turnover to proteolytic machinery. B, Pin1 gene deletion or pharmacological inhibition impairs SERCA2a and NCX-1 function, leading to increased compensatory protein production, together with diminished degradation of SERCA2a and NCX-1 contributing to protein accumulation. ECM indicates extracellular membrane; LTCC, L-type Ca2+ channel; PLN, phospholamban; RyR2, ryanodine receptor 2; and WT, wild type.
before mass spectrometry analysis in this phosphoproteomic study might have led to partial loss of information, leaving phosphorylation sites located within the digested peptide fragments. Further studies would be necessary to characterize if and under which conditions SERCA2a and NCX-1 are phosphorylated at these motifs to allow Pin1 association.

Pin1 dysregulation is implicated in diverse pathological conditions, including aging, immune response, neurodegenerative disease, and multiple cancers.10,11,34 Pin1 ubiquitous expression controls homeostasis and growth through regulation of cell proliferation, differentiation, and apoptosis in diverse tissue types.9,11,34,35 Pin1 dual function in regulating both cell signaling and protein folding accounts for why Pin1 expression levels vary widely between tissue types.10 Expression increases proportionally with cellular proliferative capacity, and Pin1 levels are upregulated in most human cancers.9,11,34 Pin1 controls cardiac progenitor cell proliferation through influence on cyclin D, cyclin B, p53, and retinoblastoma.13 Pin1 deletion caused cell cycle arrest and senescence, whereas Pin1 overexpression increases differentiation and inhibits senescence of cardiac progenitor cells.13 In stark contrast, Pin1 is highly expressed in neurons from onset of neuronal differentiation and decreases with aging, suggesting Pin1 serves a completely different purpose in this postmitotic cell context.10 A new layer of complexity has been revealed by the overtly oppositional effect of Pin1 on SERCA2a protein expression versus function.

In the myocardium, Pin1 serves a central modulator role for pathological hypertrophy and fibrosis.12,36,37 In the myocardium, Pin1 controls hypertrophic growth through regulation of Akt and Mitogen-activated protein kinase (MEK).12 Either Pin1 genetic deletion or cardiac-specific overexpression blunted hypertrophic responses induced by transaortic constriction through modulation of different pathways.12 Loss of Pin1 diminished hypertrophic signaling of Akt and MEK, whereas overexpression of Pin1 increases Rapidly Accelerated Fibrosarcoma serine/threonine-specific protein kinases (Rafl) phosphorylation on the autoinhibitory site Ser259, leading to reduced MEK activation.12 In addition, Pin1 inhibition by juglone attenuates cardiac extracellular matrix deposition in a diabetic mouse model by regulating the phosphorylation of Akt, transforming growth factor-β1, and matrix metalloproteinases.36 Furthermore, juglone treatment decreased transforming growth factor-β1 activity in the promyelocytic leukemia nuclear bodies and hypertrophic response in cardiac fibroblasts challenged with arsenic trioxide and angiotensin II,36 corroborating a role for Pin1 in regulating myocardial hypertrophy. Delayed cytosolic Ca2+ reuptake, caused by Pin1 inhibition, could be at a subpathologic level of disturbance. It could contribute to a prohypertrophic phenotype, with activation of cytosolic Ca2+ pathways through the calcineurin-Nuclear Factor of Activated T cell protein (NFAT) pathway and Ca2+-calmodulin–dependent kinase Mitogen activated protein kinase Kinase (MEF2).1,38 In the latter case, overt lack of hypertrophic phenotype in Pin1 knockout mice might be maintained by the collective influence of Pin1 on multiple regulatory cascade pathways in parallel that collectively influence cell biological features. Pin1 mediation of hypertrophic responsiveness is complex, because cardiac-specific Pin1 overexpression blunted hypertrophic response induced by transaortic constriction by influencing pathways different from those affected by Pin1 deletion.12 Preservation of homeostasis is consistent with Pin1 acting as a rheostat on multiple concurrent pathways to maintain optimal function. Cardiac-specific Pin1 overexpression could be explored as a molecular interventional strategy to enhance SERCA2a activity and normalize Ca2+ homeostasis within myocardial cells.

Acknowledgments

We thank Mansa Melvin and Julie Hu (University of Texas Southwestern) for providing assistance with Pin1−/− and Pin1+/− mice handling and transfer; Debora Eaton, Remus Berretta (Temple University), and Dr Dong Sun (New York Medical College) for technical support with isolated cardiomyocyte measurements; and all the members of the Sussman laboratory for their critical feedback.

Sources of Funding

Sacchi was supported by Swiss National Found Fellowship (P2BSP3_155252). Wang is supported by the Rees Stealy Research Foundation Fellowship. Kubli is supported by NIH grant F32 HL136064-01. Jin was supported by the American Heart Association Postdoctoral Fellowship 16POST27510010. Malter is supported by NIH grants P01HL088594. Glembotski is supported by NIH grants R01 HL75573, R01 HL104535, R01 HL127439, and P01 HL085577. Sussman is supported by NIH grants R01HL067245, R37HL091102, R01HL105759, R01HL113647, R01HL117163, P01HL085577, and R01HL122525, as well as an award from the Fondation Leducq.

Disclosures

Sussman is founder and co-owner of CardioCreate Inc. The other authors report no conflicts.

References

Pin1 Controls Cardiomyocyte Ca2+ Dynamics


SUPPLEMENTAL MATERIAL
Table S1. Antibody list.

<table>
<thead>
<tr>
<th>Use:</th>
<th>Western Blot</th>
<th>Company</th>
<th>Primary antibody dilution</th>
<th>Secondary antibody dilution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Goat</td>
<td>anti-SERCA2a</td>
<td>Santa Cruz Biotechnology (sc-8095)</td>
<td>1:1000</td>
<td>Donkey anti-goat 680 1:5000 (925-68074)</td>
</tr>
<tr>
<td>Rabbit anti NCX-1</td>
<td>Santa Cruz Biotechnology (sc-30304)</td>
<td>1:500</td>
<td>Donkey anti-rabbit 800 1:5000 (925-32213)</td>
<td></td>
</tr>
<tr>
<td>Rabbit anti CamKII</td>
<td>ThermoFisher (PA5-39732)</td>
<td>1:500</td>
<td>Donkey anti-rabbit 800 1:5000 (925-68074)</td>
<td></td>
</tr>
<tr>
<td>Rabbit anti pCamKII</td>
<td>Thermofisher (PA5-39731)</td>
<td>1:500</td>
<td>Donkey anti-rabbit 800 1:5000 (925-68074)</td>
<td></td>
</tr>
<tr>
<td>Rabbit anti-LTCC</td>
<td>Alomone Labs (ACC-003)</td>
<td>1:500</td>
<td>Donkey anti-rabbit 800 1:5000 (925-68074)</td>
<td></td>
</tr>
<tr>
<td>Rabbit anti-LTCC (pSer 1928)</td>
<td>Badrilla (A010-70)</td>
<td>1:250</td>
<td>Donkey anti-rabbit 800 1:5000 (925-68074)</td>
<td></td>
</tr>
<tr>
<td>Rabbit anti-RYR2</td>
<td>Millipore (AB9080)</td>
<td>1:500</td>
<td>Donkey anti-rabbit 800 1:5000 (925-68074)</td>
<td></td>
</tr>
<tr>
<td>Rabbit anti-RYR2 (pSer2814)</td>
<td>Badrilla (A010-31)</td>
<td>1:1000</td>
<td>Donkey anti-rabbit 800 1:5000 (925-68074)</td>
<td></td>
</tr>
<tr>
<td>Rabbit anti-RYR2 (pSer2808)</td>
<td>Badrilla (A010-30)</td>
<td>1:3000</td>
<td>Donkey anti-rabbit 800 1:5000 (925-68074)</td>
<td></td>
</tr>
<tr>
<td>Primary Antibody</td>
<td>Company</td>
<td>Primary Antibody Dilution</td>
<td>Secondary Antibody Dilution</td>
<td></td>
</tr>
<tr>
<td>------------------</td>
<td>---------</td>
<td>---------------------------</td>
<td>----------------------------</td>
<td></td>
</tr>
<tr>
<td>Mouse anti-PLN</td>
<td>Thermofisher (MA3-922)</td>
<td>1:1000</td>
<td>Donkey anti-mouse 680 1:5000 (925-68072)</td>
<td></td>
</tr>
<tr>
<td>Rabbit anti-PLN</td>
<td>Badrilla (A010-12AP)</td>
<td>1:1000</td>
<td>Donkey anti-rabbit 800 1:5000 (925-68074)</td>
<td></td>
</tr>
<tr>
<td>Rabbit anti-PLN</td>
<td>Badrilla (A010-13)</td>
<td>1:3000</td>
<td>Donkey anti-rabbit 800 1:5000 (925-68074)</td>
<td></td>
</tr>
<tr>
<td>Goat anti-GAPDH</td>
<td>SICGEN (AB0067-200)</td>
<td>1:100000</td>
<td>Donkey anti-goat 680 1:5000 (925-68074)</td>
<td></td>
</tr>
<tr>
<td>Rabbit anti-GST</td>
<td>Cell Signaling Technology (#2622)</td>
<td>1:500</td>
<td>Donkey anti-rabbit 800 1:5000 (925-68074)</td>
<td></td>
</tr>
</tbody>
</table>

**Use: PLA on Paraffin Sections**

<table>
<thead>
<tr>
<th>Primary Antibody</th>
<th>Company</th>
<th>Primary Antibody Dilution</th>
<th>Secondary Antibody Dilution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Goat anti-MYL2</td>
<td>Santa Cruz Biotechnology (sc-34490)</td>
<td>1:50</td>
<td>Donkey anti-goat 1:200 (A11055)</td>
</tr>
<tr>
<td>Mouse anti-SERCA2a</td>
<td>Thermofisher (MA3-919)</td>
<td>1:50</td>
<td>N/A</td>
</tr>
<tr>
<td>Mouse anti-NCX-1</td>
<td>Thermofisher (MA3-926)</td>
<td>1:50</td>
<td>N/A</td>
</tr>
<tr>
<td>Rabbit anti-Pin1</td>
<td>Santa Cruz Biotechnology (sc-15340)</td>
<td>1:20</td>
<td>N/A</td>
</tr>
<tr>
<td>Use: PLA on fixed cardiomyocyte</td>
<td>Company</td>
<td>Primary antibody dilution</td>
<td>Secondary antibody dilution</td>
</tr>
<tr>
<td>--------------------------------</td>
<td>---------</td>
<td>---------------------------</td>
<td>----------------------------</td>
</tr>
<tr>
<td>Goat anti-MYL2</td>
<td>Santa Cruz Biotechnology (sc-34490)</td>
<td>1:100</td>
<td>Donkey anti-goat 1:200 (A11055)</td>
</tr>
<tr>
<td>Mouse anti-SERCA2a</td>
<td>Thermofisher (MA3-919)</td>
<td>1:100</td>
<td>N/A</td>
</tr>
<tr>
<td>Mouse anti-NCX-1</td>
<td>Thermofisher (MA3-926)</td>
<td>1:100</td>
<td>N/A</td>
</tr>
<tr>
<td>Rabbit anti-Pin1</td>
<td>Santa Cruz Biotechnology (sc-15340)</td>
<td>1:50</td>
<td>N/A</td>
</tr>
</tbody>
</table>
Figure S1. pCamKII/CamKII (A), pLTCC/LTCC(B), pPLN (Ser16 and Thr 17)/PLN (C) and pRyR2 (Ser2808 and Ser2814)/RyR2 (D) expression and phosphorylation levels are unaltered in Pin1 deficient hearts. Phosphorylated Ca\(^{2+}\)/Calmodulin-dependent kinase II (pCamKII)/CamKII (A), phosphorylated L-type Ca\(^{2+}\) channel (LTCC)/LTCC(B), phosphorylated Phospholamban (PLN) (Ser16 and Thr 17)/PLN (C) and pRyR2 (Ser2808 and Ser2814)/RyR2 expression and phosphorylation levels are unaltered in Peptidyl Prolyl Isomerase (Pin1\(^{+/−}\)) and Pin1\(^{−/−}\) hearts compared to wild-type (WT) by immunoblot analysis. GAPDH used as loading control. Quantitation of protein expression shown below each representative blot as n-fold expression/WT. Data presented as mean±SEM, N=4.
Figure S2. Putative consensus motifs for Pin1 binding on SERCA2a and NCX-1 protein sequences identified by in silico analysis. (A) Sarco(endo)plasmic reticulum calcium ATPase (SERCA2a) sequence accession number NP_033852.1 (murine; NCBI protein database) or (B) Na\(^{2+}\)/Ca\(^{2+}\) exchanger 1 (NCX-1) sequence accession number NP_035536.2 (murine; NCBI protein database) analyzed for serine next to a proline residue (black squares) or threonine next to a proline (red squares).

A

**SERCA2a**

1

B

**NCX-1**

1
Figure S3 SERCA2a and NCX-1 physically interact with GST-Pin1

(A) Immunoblot for Glutathione S-Transferase (GST) (left) and GST-Pin1 (right) showing GST and GST-Pin1 protein expression at 25 and 45 kDa respectively. (B) Na\(^{2+}/Ca^{2+}\) exchanger 1 (NCX-1) and sarco(endo)plasmic reticulum calcium ATPase (SERCA2a) interacted with GST-Pin1 but not with GST upon pull-down as shown by immunoblot. β-catenin and AKT were used as positive control for the pull-down since are known targets of Pin1. N=3
Peptidyl–Prolyl Isomerase 1 Regulates $\mathrm{Ca}^{2+}$ Handling by Modulating Sarco(Endo)Plasmic Reticulum Calcium ATPase and Na$^{+}$/Ca$^{2+}$ Exchanger 1 Protein Levels and Function

Veronica Sacchi, Bingyan J. Wang, Dieter Kubli, Alexander S. Martinez, Jung-Kang Jin, Roberto Alvarez, Jr, Nirmala Hariharan, Christopher Glembotski, Takafumi Uchida, James S. Malter, Yijun Yang, Polina Gross, Chen Zhang, Steven Houser, Marcello Rota and Mark A. Sussman

*J Am Heart Assoc.* 2017;6:e006837; originally published October 10, 2017;
doi: 10.1161/JAHA.117.006837

The *Journal of the American Heart Association* is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231

Online ISSN: 2047-9980

The online version of this article, along with updated information and services, is located on the World Wide Web at:

http://jaha.ahajournals.org/content/6/10/e006837

Subscriptions, Permissions, and Reprints: The *Journal of the American Heart Association* is an online only Open Access publication. Visit the Journal at http://jaha.ahajournals.org for more information.